Posaconazole formulations not interchangeable

Tablet and oral suspension formulations of the antifungal posaconazole (Noxafil) are not interchangeable, warns the MHRA in its latest Drug Safety Update

Further information
View Noxafil drug record
Summary of Product Characteristics
MHRA Drug Safety Update

Prescribers should specify the dosage form on each prescription to avoid confusion.

Switching from oral solution to tablets, or vice versa, can result in over- or under-dosing and the risk of dose-related toxicity or lack of efficacy.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Actinic keratosis treatment recalled due to growing skin cancer concerns

Actinic keratosis treatment recalled due to growing skin cancer concerns

Healthcare professionals have been advised to stop...

PHE issues coronavirus guidance for primary care

PHE issues coronavirus guidance for primary care

Public Health England (PHE) has issued guidance for...

HPV infections fall dramatically but researchers say vaccine efficacy is 'uncertain'

HPV infections fall dramatically but researchers say vaccine efficacy is 'uncertain'

Cancer-causing HPV16 and 18 infections are now 'extremely...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.